- Home
- VLY vs DAWN Comparison
VLY vs DAWN Comparison
Compare VLY & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLY
- DAWN
- Stock Information
- Founded
- VLY 1927
- DAWN 2018
- Country
- VLY United States
- DAWN United States
- Employees
- VLY N/A
- DAWN N/A
- Industry
- VLY Major Banks
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- VLY Finance
- DAWN Health Care
- Exchange
- VLY Nasdaq
- DAWN Nasdaq
- Market Cap
- VLY N/A
- DAWN 658.9M
- IPO Year
- VLY N/A
- DAWN 2021
- Fundamental
- Price
- VLY $9.57
- DAWN $6.90
- Analyst Decision
- VLY Buy
- DAWN Strong Buy
- Analyst Count
- VLY 13
- DAWN 7
- Target Price
- VLY $10.62
- DAWN $31.57
- AVG Volume (30 Days)
- VLY 10.6M
- DAWN 1.3M
- Earning Date
- VLY 07-24-2025
- DAWN 07-29-2025
- Dividend Yield
- VLY 4.63%
- DAWN N/A
- EPS Growth
- VLY N/A
- DAWN N/A
- EPS
- VLY 0.69
- DAWN N/A
- Revenue
- VLY $1,520,316,000.00
- DAWN $161,922,000.00
- Revenue This Year
- VLY $34.12
- DAWN $17.98
- Revenue Next Year
- VLY $8.89
- DAWN $49.50
- P/E Ratio
- VLY $13.77
- DAWN N/A
- Revenue Growth
- VLY N/A
- DAWN N/A
- 52 Week Low
- VLY $7.17
- DAWN $6.08
- 52 Week High
- VLY $11.10
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- VLY 64.96
- DAWN 58.34
- Support Level
- VLY $9.45
- DAWN $6.52
- Resistance Level
- VLY $9.74
- DAWN $7.24
- Average True Range (ATR)
- VLY 0.21
- DAWN 0.26
- MACD
- VLY 0.08
- DAWN 0.07
- Stochastic Oscillator
- VLY 87.50
- DAWN 78.37
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.